SDC1 and plasma cell myeloma: Targeting CD138 (syndecan-1), a transmembrane proteoglycan highly expressed in myeloma cells and certain epithelial cells, has emerged as a therapeutic strategy, including using a drug-conjugated anti-CD138 antibody (BT026) (12).